In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis

Rodrı́guez, Juan Carlos; Ruiz, Montserrat; López, Manuela; Royo, Gloria

doi:10.1016/s0924-8579(02)00239-x

Cited by 135 publications

(101 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have reported that some strains are resistant to both linezolid and fluoroquinolones, suggesting that there might be cross-resistance (15). Crossresistance between linezolid and other second-line anti-TB drugs has not yet been reported.…”

mentioning

confidence: 98%

In Vitro Activity of Linezolid against Clinical Isolates of Mycobacterium tuberculosis, including Multidrug-Resistant and Extensively Drug-Resistant Strains from Beijing, China

et al. 2012

View full text Add to dashboard Cite

SUMMARY:The in vitro activity of linezolid was evaluated against 84 clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains, isolated from the center for tuberculosis research and treatment of the Chinese army. Linezolid showed excellent activity, with minimum inhibitory concentrations (MICs) of 0.125-0.5 mg/mL against all tested isolates. There were no differences in the MIC 50 and MIC 90 of linezolid between susceptible, isoniazidresistant, MDR, and XDR. Indeed, all of the groups displayed identical MIC 90 values of 0.25 mg/mL, which is lower than previously reported in similar studies. We conclude that linezolid may be a more effective drug against M. tuberculosis and may play an important role in treating drug-resistant tuberculosis in China.

show abstract

mentioning

confidence: 98%

In Vitro Activity of Linezolid against Clinical Isolates of Mycobacterium tuberculosis, including Multidrug-Resistant and Extensively Drug-Resistant Strains from Beijing, China

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Linezolid, the first of these compounds to be approved by the U.S. Food and Drug Administration, is licensed for the treatment of serious skin and soft tissue infections, bacteremia, and pneumonia due to resistant gram-positive bacteria. It is also active in vitro against many gram-positive actinomycetes, including Nocardia, Actinomadura, and Mycobacterium tuberculosis (2)(3)(4)(5)(6)(7)(8). Linezolid blocks bacterial ribosomal protein synthesis by a novel mechanism: binding to the 50S bacterial ribosomal subunit and preventing formation of the initiation complex for protein synthesis (9).…”

mentioning

confidence: 99%

Early and Extended Early Bactericidal Activity of Linezolid in Pulmonary Tuberculosis

Dietze

Hadad

McGee

et al. 2008

Am J Respir Crit Care Med

148

View full text Add to dashboard Cite

Rationale: Linezolid, the first oxazolidinone approved for clinical use, has effective in vitro and promising in vivo activity against Mycobacterium tuberculosis. Objectives: To evaluate the early and extended early bactericidal activity of linezolid in patients with pulmonary tuberculosis.Methods: Randomized open label trial. Thirty patients with newly diagnosed smear-positive pulmonary tuberculosis (10 per arm) were assigned to receive isoniazid (300 mg daily) and linezolid (600 mg twice daily or 600 mg once daily) for 7 days. Sputum for quantitative culture was collected for 2 days before and then daily during 7 days of study drug administration. Bactericidal activity was estimated by measuring the decline in bacilli during the first 2 days (early bactericidal activity) and the last 5 days of study drug administration (extended early bactericidal activity). Measurements and Main Results:The mean early bactericidal activity of isoniazid (0.67 log 10 cfu/ml/d) was greater than that of linezolid twice and once daily (0.26 and 0.18 log 10 cfu/ml/d, respectively). The extended early bactericidal activity of linezolid between Days 2 and 7 was minimal. Conclusions: Linezolid has modest early bactericidal activity against rapidly dividing tubercle bacilli in patients with cavitary pulmonary tuberculosis during the first 2 days of administration, but little extended early bactericidal activity. Clinical trial registered with www.clinicaltrials.gov (NCT00396084).

show abstract

“…Among them, the drug most frequently prescribed is the linezolid, which is originally an antibiotic to treat infection caused by Grampositive bacteria. It has shown good activity against drug-resistant Mycobacterium tuberculosis (M. tuberculosis) both in vitro and in vivo [16][17][18]. A number of case reports and respective studies have been performed to evaluate the efficacy of the regimens containing linezolid in the treatment of MDR and XDR TB [19][20][21].…”

Section: Off-label Use Of Anti-tb Drugsmentioning

confidence: 99%

Rational Use of Anti-Tuberculosis Drugs in the Chemotherapy Era of Drug-Resistant Tuberculosis

Xiao¹

2014

J Mycobac Dis

View full text Add to dashboard Cite

show abstract

In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis

Cited by 135 publications

References 36 publications

In Vitro Activity of Linezolid against Clinical Isolates of Mycobacterium tuberculosis, including Multidrug-Resistant and Extensively Drug-Resistant Strains from Beijing, China

In Vitro Activity of Linezolid against Clinical Isolates of Mycobacterium tuberculosis, including Multidrug-Resistant and Extensively Drug-Resistant Strains from Beijing, China

Early and Extended Early Bactericidal Activity of Linezolid in Pulmonary Tuberculosis

Rational Use of Anti-Tuberculosis Drugs in the Chemotherapy Era of Drug-Resistant Tuberculosis

Contact Info

Product

Resources

About